AKT1 and B-cell non-Hodgkin lymphoma: Therefore, when the animals were monitored for lymphomas, Eμ-myc/pim2- and Eμ-myc/AKT-expressing tumors had an accelerated disease onset compared to controls and histopathology and surface markers that were indistinguishable from those of aggressive pre-B-cell lymphomas.